Summary
Amgen Inc. (AMGN) announced on November 30, 2011, the pricing of a significant debt offering comprising €550,000,000 in Senior Notes due 2018 and £475,000,000 in Senior Notes due 2026. These notes are being issued and sold outside the United States, utilizing Regulation S under the Securities Act of 1933, and are not registered for sale within the U.S. This debt issuance provides Amgen with substantial capital in two different major currencies. The 2018 Notes carry a coupon of 4.375% paid annually, while the 2026 Notes have a higher coupon of 5.50% paid annually. The settlement for this offering is scheduled for December 5, 2011, pending customary closing conditions. Investors should note that this is a debt financing event, not an equity issuance.
Key Highlights
- 1Amgen priced an offering of €550,000,000 aggregate principal amount of Senior Notes due 2018.
- 2Amgen priced an offering of £475,000,000 aggregate principal amount of Senior Notes due 2026.
- 3The notes are being sold exclusively outside the United States under Regulation S.
- 4The 2018 Notes bear an annual interest rate of 4.375%.
- 5The 2026 Notes bear an annual interest rate of 5.50%.
- 6Settlement for the offering is expected on December 5, 2011.
- 7The filing was signed by Jonathan M. Peacock, EVP and Chief Financial Officer.